JB170
JB170 is a potent and highly specific PROTAC-mediated AURORA-A (Aurora Kinase) degrader (DC50=28 nM) by linking Alisertib, to the Cereblon-binding molecule Thalidomide. JB170 preferentially binds AURORA-A (EC50=193 nM) over AURORA-B (EC50=1.4 µM) . JB170-mediated S-phase arrest is caused specifically by AURORA-A depletion. JB170 has excellent ability to inhibit non-catalytic function of AURORA-A kinase[1].
Product Specifications
CAS Number
[2705844-82-0]
UNSPSC
12352005
Target
Aurora Kinase; PROTACs
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics; PROTAC
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/jb170.html
Purity
98.97
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
FC1=CC=CC(OC)=C1C2=NCC3=C(C4=C2C=C(C=C4)Cl)N=C(NC5=CC=C(C(OC)=C5)C(NCCOCCOCCNC(COC6=C7C(C(N(C7=O)C8CCC(NC8=O)=O)=O)=CC=C6)=O)=O)N=C3
Molecular Formula
C48H44ClFN8O11
Molecular Weight
963.36
References & Citations
[1]Adhikari B, et al. PROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase. Nat Chem Biol. 2020;16 (11) :1179-1188.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Aurora A; Cereblon
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
